← Eichor
Condition: Recurrent B Lymphoblastic Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent B Lymphoblastic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relap
Phase 1 · 8 location(s) · Shanghai Pharmaceutical Group Biological Therapy Technology · NCT06927466Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/Phase 2 · 1 location(s) · University of Colorado, Denver · NCT04544592CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leuk
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT06777979Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoi
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07105579Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transp
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT07257419Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 · 2 location(s) · Rong Tao · NCT064458033'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/L
NA · 2 location(s) · Zhu Xiaofan · NCT06355739CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT05054257Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Phase 4 · 1 location(s) · Suping ZHANG · NCT06339775Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06287229Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.